CHEMIDEX PHARMA LIMITED
Get an alert when CHEMIDEX PHARMA LIMITED files next
Leroy will email you the moment a new filing lands at Companies House — one short note per filing, nothing else.
Cash
£2.4M
-19.5% lowest in 4 filed years
Net assets
£43M
+16.4% highest in 4 filed years
Employees
49
+14% highest in 4 filed years
Profit before tax
£5.5M
-45.1% lowest in 4 filed years
Watchouts
Facts from the Companies House register and the latest accounts — not a rating
-
Annual accounts overdue
Due 2026-06-30.
Net assets
4-year trend · vs Health Care median
Accounts
4-year trend · Δ = latest vs prior filed period · latest reflected 2024-06-30
| Metric | Trend | 2021-06-30 | 2022-06-30 | 2023-06-30 | 2024-06-30 | Δ vs prior |
|---|---|---|---|---|---|---|
| Turnover | £33,000,551 | £30,681,464 | £28,630,454 | £26,397,660 | -7.8% | |
| Operating profit | £15,500,705 | £25,654,108 | £8,029,783 | £3,567,542 | -55.6% | |
| Profit before tax | £16,217,306 | £26,860,273 | £10,008,012 | £5,497,219 | -45.1% | |
| Net profit | — | — | £8,638,855 | £5,837,564 | -32.4% | |
| Cash | £12,716,273 | £8,209,459 | £3,002,926 | £2,418,625 | -19.5% | |
| Total assets less current liabilities | £16,525,101 | £28,186,252 | £36,961,999 | £47,900,533 | +29.6% | |
| Net assets | £16,363,810 | £28,024,961 | £36,850,225 | £42,893,583 | +16.4% | |
| Equity | £16,363,810 | £28,024,961 | £36,850,225 | £42,893,583 | +16.4% | |
| Average employees | 26 | 33 | 43 | 49 | +14% | |
| Wages | — | — | £3,244,154 | £4,346,511 | +34% | |
| Directors' remuneration | — | — | — | — | — |
Values shown as filed in the company's annual accounts. — indicates the figure wasn't present under that line item in that period. The Δ column is the change from the prior filed period as a percentage of |prior|; lines a company doesn't report show —. About these numbers
Ratios
Computed from the line items above — sparklines read oldest → newest
| Ratio | Trend | 2021-06-30 | 2022-06-30 | 2023-06-30 | 2024-06-30 |
|---|---|---|---|---|---|
| Operating margin | 47.0% | 83.6% | 28.0% | 13.5% | |
| Net margin | — | — | 30.2% | 22.1% | |
| Return on capital employed | 93.8% | 91.0% | 21.7% | 7.4% | |
| Current ratio | — | — | 1.99x | 2.01x | |
| Interest cover | — | — | — | 6.96x |
Margins divide P&L lines by turnover. Gearing is liabilities over total assets. Current ratio is current assets over creditors falling due within one year. Interest cover is operating profit over absolute finance costs. Sector-distribution context coming next.
Name history
Renamed 1 time since incorporation
- CHEMIDEX PHARMA LIMITED 2000-11-22 → present
- HAVENSTORE LIMITED 1982-11-08 → 2000-11-22
Audit & accounting basis
- Accounting basis
- FRS 102
- Reporting scope
- Standalone (parent only)
- Auditor
- Grant Thornton UK LLP
- Audit opinion
- Unqualified (clean)
- Going concern
- Affirmed
“Having considered the above, the directors have concluded that the group is well placed to manage the business risks, able to meeting its obligations and covenant requirements throughout the going concern assessment period being 12 months from the approval of these financial statements, and therefore adopts the going concern basis in preparing these financial statements.”
Group structure
- CHEMIDEX PHARMA LIMITED · parent
- Essential Pharma Switzerland GmbH 100%
Significant events
- “In December 2023, the group acquired the European rights to Colobreathe®, an inhaled antibiotic for the management of chronic Pseudomonas aeruginosa infections in cystic fibrosis patients, and is the first rare disease medicine to be added to the product portfolio.”
- “In April 2024, the group acquired the rights to Reminyl® oral capsules in the EEA, Thailand, South Korea and all other current markets for that product, excluding UK and Ireland, Japan and Latin America. Reminyl® is an established central nervous system (CNS) brand for the symptomatic treatment of mild to moderately severe dementia of the Alzheimer type and is a significant addition to the product portfolio of specialty CNS medicines and further expands the company's presence globally.”
- “To help fund the acquisition of the above, the group issued variable rate unsecured loan notes of £79.7m expiring in December 2025.”
Auditor, going-concern and subsidiary information is drawn from the narrative of the latest annual accounts. About these numbers
People
2 active · 10 resigned
| Name | Role | Appointed | Born | Nationality |
|---|---|---|---|---|
| RAMSDEN, Simon Stanley, Mr. | Director | 2025-09-29 | Dec 1981 | British |
| WEBB, Andrew Michael, Mr. | Director | 2022-05-01 | Jun 1983 | British |
Show 10 resigned officers
| Name | Role | Appointed | Resigned |
|---|---|---|---|
| ENGINEER, Misha | Secretary | 2013-03-27 | 2014-10-17 |
| ENGINEER, Navinchandra Jamnadas | Secretary | — | 2013-03-28 |
| ASH, Benjamin Matthew | Director | 2020-04-17 | 2025-06-27 |
| ENGINEER, Misha | Director | 2013-03-15 | 2014-10-17 |
| ENGINEER, Navinchandra Jamnadas | Director | — | 2013-03-28 |
| ENGINEER, Nikesh | Director | 2012-11-02 | 2021-06-22 |
| ENGINEER, Varsha Navinchandra | Director | — | 2013-03-28 |
| JOHNSON, Emma Jane | Director | 2023-07-01 | 2025-11-10 |
| LIBORG, Ingvild | Director | 2020-04-17 | 2022-04-30 |
| VANGSGAARD, Steen | Director | 2021-06-22 | 2023-06-30 |
Ownership
Persons with significant control
| Name | Kind | Nature of control | Notified | Status |
|---|---|---|---|---|
| Cortex 3 Guernsey Limited | Corporate entity | Shares 25–50% | 2019-12-16 | Ceased 2019-12-16 |
| Guy Semmens | Individual | Shares 75–100%, Voting 75–100%, Appoints directors | 2019-12-16 | Active |
| Mr Navinchandra Jamnadas Engineer | Individual | Shares 50–75% | 2016-04-06 | Ceased 2019-12-16 |
| Mrs Varsha Navinchandra Engineer | Individual | Shares 25–50% | 2016-04-06 | Ceased 2019-12-16 |
Filing timeline
Last 20 of 163 total filings
| Date | Type | Category | Description | |
|---|---|---|---|---|
| 2025-11-27 | TM01 | officers | Termination director company with name termination date | |
| 2025-09-30 | AP01 | officers | Appoint person director company with name date | |
| 2025-07-22 | CS01 | confirmation-statement | Confirmation statement with no updates | |
| 2025-07-08 | TM01 | officers | Termination director company with name termination date | |
| 2025-04-02 | AA | accounts | Accounts with accounts type full | |
| 2025-04-02 | MR01 | mortgage | Mortgage create with deed with charge number charge creation date | |
| 2025-04-02 | MR01 | mortgage | Mortgage create with deed with charge number charge creation date | |
| 2024-12-11 | MR04 | mortgage | Mortgage satisfy charge full | |
| 2024-12-11 | MR04 | mortgage | Mortgage satisfy charge full | |
| 2024-12-11 | MR04 | mortgage | Mortgage satisfy charge full | |
| 2024-12-11 | MR04 | mortgage | Mortgage satisfy charge full | |
| 2024-09-13 | PSC04 | persons-with-significant-control | Change to a person with significant control | |
| 2024-07-25 | CS01 | confirmation-statement | Confirmation statement with no updates | |
| 2024-07-15 | AD01 | address | Change registered office address company with date old address new address | |
| 2024-03-27 | AA | accounts | Accounts with accounts type full | |
| 2024-03-05 | PSC07 | persons-with-significant-control | Cessation of a person with significant control | |
| 2024-02-23 | RP04PSC01 | persons-with-significant-control | Second filing notification of a person with significant control | |
| 2023-07-18 | CS01 | confirmation-statement | Confirmation statement with no updates | |
| 2023-07-18 | AP01 | officers | Appoint person director company with name date | |
| 2023-07-18 | TM01 | officers | Termination director company with name termination date |
Public-record activity
Raw counts from Companies House — last 12–24 months
- Filings
- 4
- Capital events
- 0
- Officers appointed
- 1
- Officers resigned
- 1
last 12 months
last 24 months
last 12 months
last 12 months
Direct counts from the register. No score, no rating — see the Filing timeline for the underlying events.